<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="NNRTIs [46,50,51,52]. Doravirine (MK-1439A) is a new NNRTI developed by" exact="Merck" post="Company that completed two 48-week studies in 2017 [53]."/>
 <result pre="central nervous system adverse events [54]. In January 2018, US" exact="Food and Drug Administration" post="(FDA) accepted for review two new drug applications (NDAs)"/>
 <result pre="in terms of medical expenses and productivity losses [87,92]. The" exact="World Health Organization" post="has supported the monitoring of acute respiratory diseases worldwide"/>
 <result pre="description of some heterocyclic coumarinsFarmacia2001494552 45.collab: Global AIDS Update 2016Joint" exact="United Nations" post="Programme on HIV/AIDS, Geneva, SwitzerlandAvailable online: https://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016en.pdf(accessed on 17"/>
 <result pre="80.ForbesB.A.Acquisition of cytomegalovirus infection: An updateClin. Microbiol. Rev.1989220421610.1128/CMR.2.2.2042539899 81.SpruanceS.L.Viral infectionsThe" exact="Merck" post="Manual of Medical Information: Second Home EditionBeersM.H.Merck Research Laboratories,"/>
 <result pre="Merck Manual of Medical Information: Second Home EditionBeersM.H.Merck Research Laboratories," exact="Merck" post="and Co., Inc.Whitehouse Station, NJ, USA20031164 82.collab: Centers for"/>
 <result pre="OrganizationFact sheets on sustainable development goals: health target, Viral hepatitis," exact="World Health Organization" post="2017, Copenhagen, Denmark, www.euro.who.int/sdgsAvailable online: http://www.euro.who.int/__data/assets/pdf_file/0003/348222/Fact-sheet-SDG-viral-hepatitis-FINAL-en.pdf?ua=1(accessed on 23 January"/>
 <result pre="in the WHO European Region, Fact sheet â€“ July 2019," exact="World Health Organization" post="2019Available online: http://www.euro.who.int/__data/assets/pdf_file/0007/ 377251/Fact-Sheet-Hepatitis-B_2019-ENG.pdf?ua=1(accessed on 23 January 2020) 99.collab:"/>
</results>
